Formulation and Drug Delivery

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

August 28, 2020

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

Ology Bioservices Awarded US Army Contract to Manage Production of COVID-19 Vaccines and Therapeutics

August 26, 2020

The contract is valued at $106.3 million and is supported by Operation Warp Speed.

EC and Moderna Conclude Exploratory Talks on Vaccine Supply for Europe

August 26, 2020

The European Commission (EC) and Moderna have concluded exploratory talks on the potential purchase of Moderna’s COVID-19 vaccine candidate for Europeans.

Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate

August 24, 2020

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.

Novavax’s COVID-19 Vaccine Candidate Enters into Phase II Clinical Trials

August 24, 2020

The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.

EC Reaches Agreement with AstraZeneca on Purchase of COVID-19 Vaccine

August 20, 2020

EC finalizes agreement to purchase millions of doses of AstraZeneca's COVID-19 vaccine.

Novavax Signs Term Sheet with UK Gov for COVID-19 Vaccine Doses

August 20, 2020

Novavax has signed an agreement with the UK government for 60 million doses of a COVID-19 vaccine and a Phase III clinical trial.

Expanding Options for Vaccine Packaging

August 19, 2020

Plastic primary packaging could help prevent supply chain shortages associated with high demand for COVID-19 vaccines.

Cadila Pharmaceuticals Launches Biosimilar Rituximab

August 13, 2020

The company has launched its biosimilar rituximab, Ritucad, for the Indian market.

Novavax Collaborates with SK bioscience for COVID-19 Vaccine Candidate

August 13, 2020

SK bioscience will manufacture the vaccine antigen component for use in the final drug product at its vaccine facility in Andong L-house, South Korea.